6/29/2022  9:59:53 PM Chg. +0.58 Volume Bid- Ask- Market Capitalization Dividend Y. P/E Ratio
84.76USD +0.69% 66,100
Turnover: 5.62 mill.
-Bid Size: - -Ask Size: - 195.26 bill.USD - -

Business description

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis products are sold in approximately 155 countries around the world.
 

Management board & Supervisory board

CEO
Vasant Narasimhan, M.D.
Management board
Harry Kirsch, Dr. James E. Bradner, Dr. Klaus Moosmayer, Dr. Steffen Lang, Dr. Susanne Schaffert, John Tsai, M.D., Karen L. Hale, Marie-France Tschudin, Richard Saynor, Rob Kowalski, Robert Weltevreden
Supervisory board
Dr. Joerg Reinhardt, Ann Fudge, Bridgette Heller, Charles L. Sawyers, M.D., Dr. Andreas von Planta, Dr. Charlotte Pamer-Wieser, Dr. Enrico Vanni, Dr. Nancy C. Andrews, Elizabeth Doherty, Frans van Houten, Patrice Bula, Simon Moroney, Ton Buechner, William T. Winters
 

Company data

Name: Novartis AG
Address: Lichtstrasse 35,CH-4002 Basel
Phone: +41-61-324-1111
Fax: +41-61-324-8001
E-mail: -
Internet: www.novartis.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 91.90%
IPO date: 1/1/1996

Investor relations

Name: Samir Shah
IR phone: +41-61-324-7944
IR Fax: -
IR e-mail: investor.relations@n...tis.com investor.relations@novartis.com

Company calendar

CW 30 | 7/19/2022 Interim Report 2nd Quarter/6 Months
CW 44 | 10/25/2022 Interim Report 3rd Quarter/9 Months
 

Main Shareholders